ClinicalTrials.gg
Status unknownNCT05437822Updated Jul 5, 2022

Tranexamic Acid in Proximal Humeral Fractures

A Phase 4 interventional study of Tranexamic acid in Proximal Humeral Fracture and Surgical Treatment, sponsored by Elda University Hospital. Status unknown at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-07-05.

Sponsored by Elda University Hospital · Phase 4, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Jun 2022), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Shoulder Fractures with a site in Spain — 2 open to participants now, 3 under way, none of them phase 3. Shoulder Fractures · Spain.

Started
2022
with 2 others
Phase 4
Only one
of the 11
Registered
9th of 11
by date
Lead sponsor
1 of 11
Elda University Hospital

Among the 11 studies in Shoulder Fractures with a site in Spain, this one is one of 3 that started in 2022, is the only one in phase 4, and was the 9th registered.

Shoulder Fractures

113 studies on the registry are indexed under Shoulder Fractures; 30 are open to participants now.

Browse Shoulder Fractures studies →

Open to participants now

2 of the 11 studies in Shoulder Fractures with a site in Spain are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 18 Shoulder Fractures studies recruiting now, 13 (72%) set no upper age limit and 3 (17%) stop at 75 or younger; 4 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Shoulder Fractures with a site in Spain, or all of them as a file.
02

Study summary

The purpose of this study is to determine the effect of tranexamic acid (on blood loss and transfusion requirements in patients with proximal humeral fractures requiring open surgical approaches.

This a blinded, controlled, therapeutic trial in which the patients will be randomized to receive TXA or no drug intervention. The primary outcome is the estimated total blood loss.

This study presents only minimal risks for the included patients.

Read the detailed description

Studies have shown that hip fractures have a significant perioperative blood loss. Postoperative anaemia is associated with a higher morbidity and mortality.

Tranexamic acid is a safe and effective antifibrinolytic widely used to reduce blood loss in other forms of orthopaedic surgery and in traumatized patients. However, evidence on the effectiveness of TXA in shoulder fractures is more limited. Proximal humeral fractures represent a common orthopedic injury in elderly patients The goal of this study is to assess if the use of topic tranexamic acid in patients with proximal humeral fractures will result in a reduction in blood losses and blood transfusion rates.

The hypothesis is that by providing topic TXA at the end of surgery will decrease the amount of preoperative and intraoperative bleeding thereby leading to a decreased need for postoperative transfusion.

This a blinded, controlled, therapeutic trial in which the patients will be randomized to receive TXA or no drug intervention. The primary outcome is the estimated total blood loss. Secondary outcomes, need for blood transfusion, length of stay, and rate of thromboembolic events.

Candidates for the study will be consecutive patients with a diagnosis of proximal humeral fracture. All patients meeting inclusion criteria will be recruited for enrollment into the study. Informed consent will be obtained from the patient prior to randomization.

At that time, each patient will be randomized into one of two groups by an independent staff using computer generated randomization and allocation concealment. The two patient groups will include:

  1. Study group: 2 g of tranexamic acid topically infused in shoulder joint before surgical closure.
  2. Control group: no intervention Both patient groups will be blinded with regard to drug intervention. Patients will be treated surgically with internal fixation or arthroplasty. Blood transfusion criteria will remain consistent with hospital standards (Hb\<7 g/dL or >9 g/dL if symptomatic anemia). Total number of blood transfusions received will be documented upon patient discharge.

Deep vein thrombosis (DVT) prophylaxis will remain consistent with hospital standards (subcutaneous heparin from admission until 12 hours prior to surgery and beginning 6 hours after surgery).

Patients will be followed 30 days. Diagnostic studies to assess for thromboembolic events (i.e. DVT, pulmonary embolism (PE), and stroke) will be ordered only if the patient develops clinical signs or symptoms that justify their use.

03

Conditions studied

  • Proximal Humeral Fracture
  • Surgical Treatment

Browse trials for

Keywords

  • proximal humeral fracture
  • surgical treatment
  • Tranexamic acid
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Acute proximal humeral fracture
  • Age over 18 years

Exclusion criteria

Exclusion Criteria:

  • Concomitant fracture
  • Refusal to receive blood products
  • Allergy for tranexamic acid
  • Severe hepatic dysfunction (/ALT >60)
  • Renal function impairment (serum creatinine > 2 mg/dL or \<30 mL/min),) or kidney transplant
  • Active acute thromboembolic event in the past 12 months (Deep Vein Thrombosis, Pulmonary)
  • Active coronary artery disease or cerebrovascular accident (event in the past 12 months).
  • Coronary stents
  • History of hypercoagulability
  • Coagulopathy ( > 1.4)
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    TXA group

    Tranexamic acid, a topic dose of 2 g diluted in 50 mL saline solution infused in shoulder joint

    Drug: Tranexamic acid

  • No intervention
    Control group

    In the control group will not be administered TXA or any other drugs.

Interventions

06

What researchers measure

Primary outcomes

  1. Perioperative blood loss

    Measurement of loss (in mL), calculated with mathematical formulas proposed by Nadler and Good

    Time frame: Hospital stay, from admission to third postoperative day.

Secondary outcomes

  1. Blood transfusion rate

    Number of patients needing blood transfusion

    Time frame: Hospital stay, from admission to third postoperative day

  2. Infection rate

    Number of patients with surgical or medical infections (wound, pneumonia, urinary tract)

    Time frame: 90 postoperative days

  3. Thrombotic event rate

    Number of patients with postoperative thrombotic event (Deep Venous Thrombosis, Pulmonary Embolism, Myocardial Infarction, Stroke)

    Time frame: 90 postoperative days.

07

Study locations

1 of 1 sites recruiting
  • Elda University Hospital
    Elda, Alicante 03600, Spain
    Recruiting
    • Alejandro Lizaur-Utrilla, PhD, MD · Contactlizaur1@telefonica.net · +34 966989019
    • Alejandro Lizaur-Utrilla, PhD, MD · Principal investigator
    • Emilio Sebastia-Forcada, MD · Sub investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2022 (actual). Primary completion is estimated for Jun 2023, 11 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 18, 2022
First posted
Jun 29, 2022
StartActual
Jun 29, 2022
Primary completionEst.
Jun 21, 2023
CompletionEst.
Jun 24, 2023
Last update
Jul 5, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 5, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05437822
Lead sponsor
Elda University Hospital
Collaborators
Universidad Miguel Hernandez de Elche
Responsible party
Alejandro Lizaur-Utrilla, PhD, MD (Head of Orthopaedic Surgery Department, Elda University Hospital) — Principal investigator
First posted
Jun 29, 2022
Start date
Jun 29, 2022
Primary completion
Jun 21, 2023 (estimated)
Completion
Jun 24, 2023 (estimated)
Last update
Jul 5, 2022

Study contacts

Alejandro Lizaur-Utrilla, MD
Contact
lizaur1@telefonica.net
+34 966989019
Emilio Sebastia-Forcada, MD
Contact
lizaur1@telefonica.net
+34 966989019
Alejandro Lizaur Utrilla, MD
principal investigator · Orthopaedic Surgery Department, Elda University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tranexamic Acid

Start the discussion